MG 1111

Drug Profile

MG 1111

Alternative Names: MG1111

Latest Information Update: 13 Oct 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Green Cross
  • Class Varicella vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Varicella zoster virus infections

Most Recent Events

  • 01 Mar 2015 Phase-I clinical trials in Varicella zoster virus infections (Prevention, In volunteers) in South Korea (Parenteral)
  • 24 Feb 2015 Green Cross plans a phase I trial for Varicella zoster virus infections (Prevention) in South Korea (NCT02367638)
  • 23 Aug 2013 Preclinical trials in Varicella zoster virus infections in South Korea (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top